Scribe Therapeutics (SCTX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Scribe Therapeutics (NASDAQ: SCTX) recently:

• 8/18/2026 – Scribe Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $50.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $60.00 price target on the stock.
• 8/18/2026 – Scribe Therapeutics was upgraded by Wells Fargo & Company to “strong-buy”.
• 8/18/2026 – Scribe Therapeutics was upgraded by Guggenheim to “strong-buy”.
• 8/18/2026 – Scribe Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $37.00 price target on the stock.
• 8/1/2026 – Scribe Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Transactions at Scribe Therapeutics

In other news, CFO David Parrot purchased 2,666 shares of the business’s stock in a transaction dated Thursday, July 23rd. The stock was acquired at an average price of $15.00 per share, with a total value of $39,990.00. Following the purchase, the chief financial officer directly owned 1,333 shares of the company’s stock, valued at $19,995. This represents a -200.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Behzad Aghazadeh bought 2,383,333 shares of the company’s stock in a transaction on Friday, July 24th. The shares were acquired at an average price of $15.15 per share, with a total value of $36,107,494.95. Following the completion of the acquisition, the director directly owned 3,080,983 shares in the company, valued at $46,676,892.45. This represents a 341.62% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 3,727,237 shares of company stock worth $56,291,746.

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.